Ballentine Partners, LLC Erasca, Inc. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 13,996 shares of ERAS stock, worth $32,330. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,996
Previous 15,769
11.24%
Holding current value
$32,330
Previous $20,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
217MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$52.5 Million1.52% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.3MShares$47 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$41.2 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$34.7 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$33.5 Million0.63% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $282M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...